nach oben

Erschienen in:

28.11.2021

The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the ‘GO-UP’ study

verfasst von: Panagiotis Athanassiou, Anastasios Kotrotsios, Ioannis Kallitsakis, Andreas Bounas, Theodoros Dimitroulas, Alexandros Garyfallos, Maria G. Tektonidou, Giorgos Vosvotekas, Achilleas Livieratos, Evangelia Petrikkou, Gkikas Katsifis

Erschienen in: Quality of Life Research | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To examine the impact of golimumab, on work productivity, activity limitation, and quality of life (QoL) in patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA).

Methods

This real-world, multicenter, prospective study consecutively enrolled adult consented work-active patients with axSpA or PsA, newly initiated on golimumab as per the approved label. Prior receipt of > 1 prior biologic, or switching from another tumor-necrosis factor inhibitor due to primary non-response or safety reasons was not allowed. The Work Productivity and Activity Impairment-Specific Health Problem and the EuroQol 5-Dimensions (EQ-5D)-5-Level instruments were completed by the patients to assess the impact of golimumab on work productivity and activity impairment, and generic QoL, respectively.

Results

Overall, 121 eligible patients (mean age: 45.4 years; median disease duration: 11.3 months), 51 diagnosed with PsA and 70 with axSpA, were enrolled by 19 rheumatologists. Over a 11.9-month median observation period, < 1% of injections were missed (as collected by patient diaries), and the 12-month golimumab retention rate was 91.7%. At 3, 6, and 12 months post baseline, in the overall population, work productivity loss improved by a median of 31.4%, 44.2%, and 50.0%; activity impairment improved by 40.0%, 40.0%, and 50.0%; and the EQ-5D UK-weighted utility index improved by 0.24, 0.32, and 0.36 points, respectively (p < 0.001 for all). Statistically significant improvements in these measures were also noted in the PsA and axSpA subpopulations.

Conclusion

In the routine care in Greece, golimumab displays beneficial effects on work productivity, daily activities, and QoL in work-active patients with axSpA and PsA.

Trial registration

Trial registration number and date of registration: As per the local regulations the study has been registered at the national registry for non-interventional studies https://www.dilon.sfee.gr/studiesp_d.php?meleti_id=MK8259-6083.

van der Linden, S., Valkenburg, H. A., & Cats, A. (1984). Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis and Rheumatism, 27(4), 361–368. https://doi.org/10.1002/art.1780270401CrossRefPubMed

Rudwaleit, M., van der Heijde, D., Landewé, R., Listing, J., Akkoc, N., Brandt, J., Braun, J., Chou, C. T., Collantes-Estevez, E., Dougados, M., Huang, F., Gu, J., Khan, M. A., Kirazli, Y., Maksymowych, W. P., Mielants, H., Sørensen, I. J., Ozgocmen, S., Roussou, E., … Sieper, J. (2009). The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Annals of the Rheumatic Diseases, 68(6), 777–783. https://doi.org/10.1136/ard.2009.108233CrossRefPubMed

Braun, J. (2018). Axial spondyloarthritis including ankylosing spondylitis. Rheumatology (Oxford, England). https://doi.org/10.1093/rheumatology/key079CrossRef

Stolwijk, C., van Onna, M., Boonen, A., & van Tubergen, A. (2016). Global prevalence of spondyloarthritis: A systematic review and meta-regression analysis. Arthritis Care & Research, 68(9), 1320–1331. https://doi.org/10.1002/acr.22831CrossRef

De Angelis, R., Salaffi, F., & Grassi, W. (2007). Prevalence of spondyloarthropathies in an Italian population sample: A regional community-based study. Scandinavian Journal of Rheumatology, 36(1), 14–21. https://doi.org/10.1080/03009740600904243CrossRefPubMed

Gudu, T., & Gossec, L. (2018). Quality of life in psoriatic arthritis. Expert Review of Clinical Immunology, 14(5), 405–417. https://doi.org/10.1080/1744666X.2018.1468252CrossRefPubMed

Strand, V., & Singh, J. A. (2017). Patient Burden of Axial Spondyloarthritis. Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases, 23(7), 383–391. https://doi.org/10.1097/RHU.0000000000000589CrossRef

Michelsen, B., Fiane, R., Diamantopoulos, A. P., Soldal, D. M., Hansen, I. J., Sokka, T., Kavanaugh, A., & Haugeberg, G. (2015). A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PLoS One, 10(4), e0123582. https://doi.org/10.1371/journal.pone.0123582CrossRefPubMedPubMedCentral

Husted, J. A., Thavaneswaran, A., Chandran, V., Eder, L., Rosen, C. F., Cook, R. J., & Gladman, D. D. (2011). Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis. Arthritis Care & Research, 63(12), 1729–1735. https://doi.org/10.1002/acr.20627CrossRef

10.

Khraishi, M., MacDonald, D., Rampakakis, E., Vaillancourt, J., & Sampalis, J. S. (2011). Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts. Clinical Rheumatology, 30(7), 877–885. https://doi.org/10.1007/s10067-011-1692-7CrossRefPubMed

11.

Mease, P. J., Liu, M., Rebello, S., Kang, H., Yi, E., Park, Y., & Greenberg, J. D. (2019). Comparative disease burden in patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis: data from two corrona registries. Rheumatology and Therapy, 6(4), 529–542. https://doi.org/10.1007/s40744-019-00172-9CrossRefPubMedPubMedCentral

12.

Moltó, A., & Dougados, M. (2018). Comorbidities in spondyloarthritis including psoriatic arthritis. Best practice & research. Clinical Rheumatology, 32(3), 390–400. https://doi.org/10.1016/j.berh.2018.09.002CrossRefPubMed

13.

Boonen, A. (2006). A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. Nature Clinical Practice. Rheumatology, 2(10), 546–553. https://doi.org/10.1038/ncprheum0297CrossRefPubMed

14.

Krüger, K., Burmester, G. R., Wassenberg, S., Bohl-Bühler, M., & Thomas, M. H. (2019). Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Non-interventional study GO-NICE in Germany. Rheumatology International, 39(1), 131–140. https://doi.org/10.1007/s00296-018-4180-4CrossRefPubMed

15.

Smolen, J. S., Schöls, M., Braun, J., Dougados, M., FitzGerald, O., Gladman, D. D., Kavanaugh, A., Landewé, R., Mease, P., Sieper, J., Stamm, T., Wit, M., Aletaha, D., Baraliakos, X., Betteridge, N., Bosch, F., Coates, L. C., Emery, P., Gensler, L. S., … van der Heijde, D. (2018). Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 77(1), 3–17. https://doi.org/10.1136/annrheumdis-2017-211734CrossRefPubMed

16.

Gossec, L., Smolen, J. S., Ramiro, S., de Wit, M., Cutolo, M., Dougados, M., Emery, P., Landewé, R., Oliver, S., Aletaha, D., Betteridge, N., Braun, J., Burmester, G., Cañete, J. D., Damjanov, N., FitzGerald, O., Haglund, E., Helliwell, P., Kvien, T. K., … van der Heijde, D. (2016). European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the Rheumatic Diseases, 75(3), 499–510. https://doi.org/10.1136/annrheumdis-2015-208337CrossRefPubMed

17.

Garrido-Cumbrera, M., Hillmann, O., Mahapatra, R., Trigos, D., Zajc, P., Weiss, L., Bostynets, G., Gossec, L., & Coates, L. C. (2017). Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients. Rheumatology and Therapy, 4(2), 219–231. https://doi.org/10.1007/s40744-017-0066-2CrossRefPubMedPubMedCentral

18.

Ward, M. M., Deodhar, A., Gensler, L. S., Dubreuil, M., Yu, D., Khan, M. A., Haroon, N., Borenstein, D., Wang, R., Biehl, A., Fang, M. A., Louie, G., Majithia, V., Ng, B., Bigham, R., Pianin, M., Shah, A. A., Sullivan, N., Turgunbaev, M., … Caplan, L. (2019). 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis & Rheumatology (Hoboken, N.J.), 71(10), 1599–1613. https://doi.org/10.1002/art.41042CrossRef

19.

Gossec, L., Baraliakos, X., Kerschbaumer, A., de Wit, M., McInnes, I., Dougados, M., Primdahl, J., McGonagle, D. G., Aletaha, D., Balanescu, A., Balint, P. V., Bertheussen, H., Boehncke, W. H., Burmester, G. R., Canete, J. D., Damjanov, N. S., Kragstrup, T. W., Kvien, T. K., Landewé, R., … Smolen, J. S. (2020). EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Annals of the Rheumatic Diseases, 79(6), 700–712. https://doi.org/10.1136/annrheumdis-2020-217159CrossRefPubMed

20.

Simponi, Summary of Product Characteristics. Retrieved April 8, 2021, from https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf

21.

Hernandez, M. V., Sanchez-Piedra, C., Garcia-Magallon, B., Cuende, E., Manero, J., Campos-Fernandez, C., Martin-Domenech, R., Del Pino-Montes, J., Manrique, S., Castro-Villegas, M. C., Ruiz-Montesinos, D., Sanchez-Alonso, F., Diaz-Gonzalez, F., Cea-Calvo, L., Gómez-Reino, J. J., BIOBADASER Study. (2019). Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry. Rheumatology International, 39(3), 509–515. https://doi.org/10.1007/s00296-018-4177-zCrossRefPubMed

22.

Luttropp, K., Dozier, M., Justo, N., Cornillie, F., Kachroo, S., Govoni, M., Salomonsson, S., Black, C. M., & Khalifa, A. (2019). Real-world treatment persistence of golimumab in the management of immune-mediated rheumatic diseases in Europe: A systematic literature review. British Medical Journal Open, 9(5), e027456. https://doi.org/10.1136/bmjopen-2018-027456CrossRef

23.

Reilly, M. C., Zbrozek, A. S., & Dukes, E. M. (1993). The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics, 4(5), 353–365. https://doi.org/10.2165/00019053-199304050-00006CrossRefPubMed

24.

Reilly Associates. WPAI Translation. Retrieved April 8, 2021, http://www.reillyassociates.net/WPAI_Translations.html.

25.

EuroQol Research Foundation. EQ-5D-5L, About. Retrieved April 8, 2021, from https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/.

26.

Doward, L. C., Spoorenberg, A., Cook, S. A., Whalley, D., Helliwell, P. S., Kay, L. J., McKenna, S. P., Tennant, A., van der Heijde, D., & Chamberlain, M. A. (2003). Development of the ASQoL: A quality of life instrument specific to ankylosing spondylitis. Annals of the Rheumatic Diseases, 62(1), 20–26. https://doi.org/10.1136/ard.62.1.20CrossRefPubMedPubMedCentral

27.

Graham, J. E., Rouse, M., Twiss, J., McKenna, S. P., & Vidalis, A. A. (2015). Greek adaptation and validation of the Ankylosing Spondylitis Quality of Life (ASQoL) measure. Hippokratia, 19(2), 119–124.PubMedPubMedCentral

28.

McKenna, S. P., Doward, L. C., Whalley, D., Tennant, A., Emery, P., & Veale, D. J. (2004). Development of the PsAQoL: A quality of life instrument specific to psoriatic arthritis. Annals of the Rheumatic Diseases, 63(2), 162–169. https://doi.org/10.1136/ard.2003.006296CrossRefPubMedPubMedCentral

29.

Heaney, Α, Stepanous, J., McKenna, S. P., Athanassiou, P., & Vidalis, A. A. (2017). Translation and validation of the greek Psoriatic Arthritis Quality of Life Scale. Psychiatriki, 28(3), 219–225. https://doi.org/10.22365/jpsych.2017.283.219CrossRef

30.

Garrett, S., Jenkinson, T., Kennedy, L. G., Whitelock, H., Gaisford, P., & Calin, A. (1994). A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology, 21(12), 2286–2291.PubMed

31.

Yfantopoulos, J. N., & Chantzaras, A. E. (2017). Validation and comparison of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in Greece. The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care, 18(4), 519–531. https://doi.org/10.1007/s10198-016-0807-0CrossRefPubMed

32.

Salaffi, F., Ciapetti, A., Carotti, M., Gasparini, S., & Gutierrez, M. (2014). Disease activity in psoriatic arthritis: Comparison of the discriminative capacity and construct validity of six composite indices in a real world. BioMed Research International, 2014, 528105. https://doi.org/10.1155/2014/528105CrossRefPubMedPubMedCentral

33.

van Gestel, A. M., Prevoo, M. L., van’t Hof, M. A., van Rijswijk, M. H., van de Putte, L. B., & van Riel, P. L. (1996). Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis and Rheumatism, 39(1), 34–40. https://doi.org/10.1002/art.1780390105CrossRefPubMed

34.

Fleischmann, R. M., van der Heijde, D., Gardiner, P. V., Szumski, A., Marshall, L., & Bananis, E. (2017). DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable. RMD Open, 3(1), e000382. https://doi.org/10.1136/rmdopen-2016-000382CrossRefPubMedPubMedCentral

35.

Krüger, K., Remstedt, S., Thiele, A., & Klaudius, I. (2017). Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Interim Results from a Non-Interventional Trial in Germany [abstract]. Arthritis Rheumatol 69 (suppl 10). Retrieved March 4, 2018, from http://acrabstracts.org/abstract/golimumab-improves-work-productivity-and-activity-impairment-in-patients-with-rheumatoid-arthritis-ra-ankylosing-spondylitis-as-and-psoriatic-arthritis-psa-interim-results-from-a-non-intervent/.

36.

Xu, H., & Yin, J. (2019). HLA risk alleles and gut microbiome in ankylosing spondylitis and rheumatoid arthritis Best practice & research. Clinical Rheumatology, 33(6), 101499. https://doi.org/10.1016/j.berh.2020.101499CrossRefPubMed

37.

Colmegna, I., Cuchacovich, R., & Espinoza, L. R. (2004). HLA-B27-associated reactive arthritis: Pathogenetic and clinical considerations. Clinical Microbiology Reviews, 17(2), 348–369. https://doi.org/10.1128/CMR.17.2.348-369.2004CrossRefPubMedPubMedCentral

38.

Wakefield, D., Clarke, D., & McCluskey, P. (2021). Recent Developments in HLA B27 Anterior Uveitis. Frontiers in Immunology, 11, 608134. https://doi.org/10.3389/fimmu.2020.608134CrossRefPubMedPubMedCentral

39.

Krueger, K., Remstedt, S., Thiele, A., & Hohenberger, S. (2020). Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany. Journal of Comparative Effectiveness Research, 9(12), 891–902. https://doi.org/10.2217/cer-2020-0092CrossRefPubMed

40.

Claudepierre, P., Van den Bosch, F., Sarzi-Puttini, P., Vastesaeger, N., Govoni, M., & Kachroo, S. (2019). Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort. International Journal of Rheumatic Diseases, 22(6), 995–1001. https://doi.org/10.1111/1756-185X.13526CrossRefPubMed

41.

Dejaco, C., Mueller, T., Zamani, O., Kurtz, U., Egger, S., Resch-Passini, J., Totzauer, A., Eisterer, W., Yazdani-Biuki, B., Schwingenschloegl, T., Peichl, P., Kraus, A., Naerr, G. W., & Rickert, V. (2018). FRI0108 Golimumab improves work productivity and activity and quality of life in patients with rheumatoid arthritis (RA), psoriasis arthritis (PSA) and axial spondyloarthritis (AxSPA): interim results from a non-interventional study in Austria (Go Active). Annals of Rheumatic Diseases, 77(598), 2–599. https://doi.org/10.1136/annrheumdis-2018-eular.2411CrossRef

42.

Szende, A., Janssen, B., & Cabasés, J. (2014). Self-Reported Population Health: An International Perspective Based on EQ-5D. Springer Dordrecht Heidelberg New York, London. 2014. Springer Open. Retrieved September 17, 2020 from https://eq-5dpublications.euroqol.org/download?id=0_54006&fileId=54415.

43.

Kontodimopoulos, N., Pappa, E., Niakas, D., Yfantopoulos, J., Dimitrakaki, C., & Tountas, Y. (2008). Validity of the EuroQoL (EQ-5D) instrument in a Greek general population. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 11(7), 1162–1169. https://doi.org/10.1111/j.1524-4733.2008.00356.xCrossRef

44.

Sidiropoulos, P., Bounas, A., Athanassiou, P., Koutsianas, C., Petrikkou, E., Kaltsonoudis, E., Drosos, A., & Vassilopoulos, D. (2020). Correlation of patient preferences to treatment outcomes in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors in Greece. Clinical Rheumatology, 39(12), 3643–3652. https://doi.org/10.1007/s10067-020-05171-8CrossRefPubMed

45.

Iannone, F., Santo, L., Anelli, M. G., Bucci, R., Semeraro, A., Quarta, L., D’Onofrio, F., Marsico, A., Carlino, G., Casilli, O., Cacciapaglia, F., Zuccaro, C., Falappone, P. C., Cantatore, F. P., Muratore, M., & Lapadula, G. (2017). Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Seminars in Arthritis and Rheumatism, 47(1), 108–114. https://doi.org/10.1016/j.semarthrit.2017.01.008CrossRefPubMed

46.

Manara, M., Caporali, R., Favalli, E. G., Grosso, V., Atzeni, F., Sarzi Puttini, P., Gorla, R., Bazzani, C., Fusaro, E., Pellerito, R., Rocchetta, P. A., & Sinigaglia, L. (2017). Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: Data from the LORHEN registry. Clinical and Experimental Rheumatology, 35(5), 804–809.PubMed

47.

Thomas, K., Flouri, I., Repa, A., Fragiadaki, K., Sfikakis, P. P., Koutsianas, C., Kaltsonoudis, E., Voulgari, P. V., Drosos, A. A., Petrikkou, E., Sidiropoulos, P., & Vassilopoulos, D. (2018). High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: Real world data from 328 patients. Clinical and Experimental Rheumatology, 36(2), 254–262.PubMed

48.

Sieper, J., van der Heijde, D., Dougados, M., Maksymowych, W. P., Scott, B. B., Boice, J. A., Berd, Y., Bergman, G., Curtis, S., Tzontcheva, A., Huyck, S., & Weng, H. H. (2015). A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis & Rheumatology (Hoboken, N.J.), 67(10), 2702–2712. https://doi.org/10.1002/art.39257CrossRef

49.

Van den Bosch, F., Flipo, R. M., Braun, J., Vastesaeger, N., Kachroo, S., & Govoni, M. (2019). Clinical and quality of life improvements with golimumab or infliximab in a real-life ankylosing spondylitis population: The QUO-VADIS study. Clinical and Experimental Rheumatology, 37(2), 199–207.PubMed

50.

Reveille, J. D., Deodhar, A., Caldron, P. H., Dudek, A., Harrison, D. D., Kim, L., Lo, K. H., Leu, J. H., & Hsia, E. C. (2019). Safety and efficacy of intravenous golimumab in adults with ankylosing spondylitis: Results through 1 year of the GO-ALIVE study. The Journal of Rheumatology, 46(10), 1277–1283. https://doi.org/10.3899/jrheum.180718CrossRefPubMed

51.

Kavanaugh, A., McInnes, I. B., Krueger, G. G., Gladman, D., Beutler, A., Gathany, T., Mack, M., Tandon, N., Han, C., & Mease, P. (2013). Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: Findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care & Research, 65(10), 1666–1673. https://doi.org/10.1002/acr.22044CrossRef

52.

van der Heijde, D., Deodhar, A., Braun, J., Mack, M., Hsu, B., Gathany, T. A., Inman, R. D., Han, C., & GO-RAISE investigators,. (2014). The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. The Journal of Rheumatology, 41(6), 1095–1103. https://doi.org/10.3899/jrheum.131003CrossRefPubMed

53.

Huang, J. C., Qian, B. P., Qiu, Y., Wang, B., Yu, Y., Zhu, Z. Z., Hu, J., & Qu, Z. (2017). Quality of life and correlation with clinical and radiographic variables in patients with ankylosing spondylitis: A retrospective case series study. BMC Musculoskeletal Disorders, 18(1), 352. https://doi.org/10.1186/s12891-017-1711-1CrossRefPubMedPubMedCentral

54.

Bodur, H., Ataman, S., Rezvani, A., Buğdaycı, D. S., Cevik, R., Birtane, M., Akıncı, A., Altay, Z., Günaydın, R., Yener, M., Koçyiğit, H., Duruöz, T., Yazgan, P., Cakar, E., Aydın, G., Hepgüler, S., Altan, L., Kırnap, M., Olmez, N., … Günendi, Z. (2011). Quality of life and related variables in patients with ankylosing spondylitis. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 20(4), 543–549. https://doi.org/10.1007/s11136-010-9771-9CrossRef

55.

Dean, L. E., Macfarlane, G. J., & Jones, G. T. (2018). Five potentially modifiable factors predict poor quality of life in ankylosing spondylitis: results from the scotland registry for ankylosing spondylitis. The Journal of Rheumatology, 45(1), 62–69. https://doi.org/10.3899/jrheum.160411CrossRefPubMed

56.

Machado, P., & van der Heijde, D. (2011). How to measure disease activity in axial spondyloarthritis? Current Opinion in Rheumatology, 23(4), 339–345. https://doi.org/10.1097/BOR.0b013e3283470f23CrossRefPubMed

57.

Nell-Duxneuner, V. P., Stamm, T. A., Machold, K. P., Pflugbeil, S., Aletaha, D., & Smolen, J. S. (2010). Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Annals of the Rheumatic Diseases, 69(3), 546–549. https://doi.org/10.1136/ard.2009.117945CrossRefPubMed

58.

Schoels, M. M., Aletaha, D., Alasti, F., & Smolen, J. S. (2016). Disease activity in psoriatic arthritis (PsA): Defining remission and treatment success using the DAPSA score. Annals of the Rheumatic Diseases, 75(5), 811–818. https://doi.org/10.1136/annrheumdis-2015-207507CrossRefPubMed

59.

Tucker, L. J., Coates, L. C., & Helliwell, P. S. (2019). Assessing disease activity in psoriatic arthritis: A literature review. Rheumatology and Therapy, 6(1), 23–32. https://doi.org/10.1007/s40744-018-0132-4CrossRefPubMed

Titel: The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the ‘GO-UP’ study
verfasst von: Panagiotis Athanassiou
Anastasios Kotrotsios
Ioannis Kallitsakis
Andreas Bounas
Theodoros Dimitroulas
Alexandros Garyfallos
Maria G. Tektonidou
Giorgos Vosvotekas
Achilleas Livieratos
Evangelia Petrikkou
Gkikas Katsifis
Publikationsdatum: 28.11.2021
Verlag: Springer International Publishing
Erschienen in: Quality of Life Research / Ausgabe 5/2022
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-021-03044-4

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the ‘GO-UP’ study

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2022

Validation and comparison of five preference-based measures among age-related macular degeneration patients: evidence from mainland China

Psychopathology and health-related quality of life as patient-reported treatment outcomes: evaluation of concordance between the Brief Symptom Inventory (BSI) and the Short Form-36 (SF-36) in psychiatric outpatients

The QALY is ableist: on the unethical implications of health states worse than dead

What difference does multiple imputation make in longitudinal modeling of EQ-5D-5L data? Empirical analyses of simulated and observed missing data patterns

Joint modelling with competing risks of dropout for longitudinal analysis of health-related quality of life in cancer clinical trials

Is malnutrition a determining factor of health-related quality of life in hemodialysis patients? A cross-sectional design examining relationships with a comprehensive assessment of nutritional status